(Q26744404)

English

Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials

scientific article

In more languages

Statements

scholarly article

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials (English)

0 references

influenza vaccine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Raina MacIntyre

5

object named as

C Raina MacIntyre

0 references

David J Muscatello

3

object named as

David J Muscatello

0 references

Abrar Ahmad Chughtai

2

object named as

Abrar A Chughtai

0 references

1

object named as

Aye M Moa

0 references

4

object named as

Robin M Turner

0 references

language of work or name

0 references

publication date

29 July 2016

0 references

0 references

34

0 references

35

0 references

4092-102

0 references

Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

The evolving history of influenza viruses and influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

The rationale for quadrivalent influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Multiple genotypes of influenza B virus circulated between 1979 and 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011-12 season

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Estimates of influenza vaccine effectiveness for 2007-2008 from Canada's sentinel surveillance system: cross-protection against major and minor variants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Influenza vaccination in young children reduces influenza-associated hospitalizations in older adults, 2002-2006.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Herd protection against influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

The economic value of a quadrivalent versus trivalent influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Changes in the hemagglutinins and neuraminidases of human influenza B viruses isolated in Italy during the 2001-02, 2002-03, and 2003-04 seasons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Molecular characterization of influenza B viruses circulating in northern Italy during the 2001-2002 epidemic season

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Immune response to inactivated influenza virus vaccine: antibody reactivity with epidemic influenza B viruses of two highly distinct evolutionary lineages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Biology of immune responses to vaccines in elderly persons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.064

7 January 2021

Identifiers

10.1016/J.VACCINE.2016.06.064

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26744404&oldid=2143192880"